Risk of Estrogen Receptor–Positive and –Negative Breast Cancer and Single–Nucleotide Polymorphism 2q35-rs13387042
Background A recent genome-wide association study identified single-nucleotide polymorphism (SNP) 2q35-rs13387042 as a marker of susceptibility to estrogen receptor (ER)–positive breast cancer. We attempted to confirm this association using the Breast Cancer Association Consortium. Methods 2q35-rs13...
Saved in:
| Published in | JNCI : Journal of the National Cancer Institute Vol. 101; no. 14; pp. 1012 - 1018 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Cary, NC
Oxford University Press
15.07.2009
Oxford Publishing Limited (England) |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Background A recent genome-wide association study identified single-nucleotide polymorphism (SNP) 2q35-rs13387042 as a marker of susceptibility to estrogen receptor (ER)–positive breast cancer. We attempted to confirm this association using the Breast Cancer Association Consortium. Methods 2q35-rs13387042 SNP was genotyped for 31 510 women with invasive breast cancer, 1101 women with ductal carcinoma in situ, and 35 969 female control subjects from 25 studies. Odds ratios (ORs) were estimated by logistic regression, adjusted for study. Heterogeneity in odds ratios by each of age, ethnicity, and study was assessed by fitting interaction terms. Heterogeneity by each of invasiveness, family history, bilaterality, and hormone receptor status was assessed by subclassifying case patients and applying polytomous logistic regression. All statistical tests were two-sided. Results We found strong evidence of association between rs13387042 and breast cancer in white women of European origin (per-allele OR = 1.12, 95% confidence interval [CI] = 1.09 to 1.15; Ptrend = 1.0 × 10−19). The odds ratio was lower than that previously reported (P = .02) and did not vary by age or ethnicity (all P ≥ .2). However, it was higher when the analysis was restricted to case patients who were selected for a strong family history (P = .02). An association was observed for both ER-positive (OR = 1.14, 95% CI = 1.10 to 1.17; P = 10−15) and ER-negative disease (OR = 1.10, 95% CI = 1.04 to 1.15; P = .0003) and both progesterone receptor (PR)–positive (OR = 1.15, 95% CI = 1.11 to 1.19; P = 5 × 10−14) and PR-negative disease (OR = 1.10, 95% CI = 1.06 to 1.15; P = .00002). Conclusion The rs13387042 is associated with both ER-positive and ER-negative breast cancer in European women. |
|---|---|
| AbstractList | Background
A recent genome-wide association study identified single-nucleotide polymorphism (SNP) 2q35-rs13387042 as a marker of susceptibility to estrogen receptor (ER)-positive breast cancer. We attempted to confirm this association using the Breast Cancer Association Consortium.
Methods
2q35-rs13387042 SNP was genotyped for 31 510 women with invasive breast cancer, 1101 women with ductal carcinoma in situ, and 35 969 female control subjects from 25 studies. Odds ratios (ORs) were estimated by logistic regression, adjusted for study. Heterogeneity in odds ratios by each of age, ethnicity, and study was assessed by fitting interaction terms. Heterogeneity by each of invasiveness, family history, bilaterality, and hormone receptor status was assessed by subclassifying case patients and applying polytomous logistic regression. All statistical tests were two-sided.
Results
We found strong evidence of association between rs13387042 and breast cancer in white women of European origin (per-allele OR = 1.12, 95% confidence interval [CI] = 1.09 to 1.15; P
trend = 1.0 × 10−19). The odds ratio was lower than that previously reported (P = .02) and did not vary by age or ethnicity (all P ≥ .2). However, it was higher when the analysis was restricted to case patients who were selected for a strong family history (P = .02). An association was observed for both ER-positive (OR = 1.14, 95% CI = 1.10 to 1.17; P = 10−15) and ER-negative disease (OR = 1.10, 95% CI = 1.04 to 1.15; P = .0003) and both progesterone receptor (PR)-positive (OR = 1.15, 95% CI = 1.11 to 1.19; P = 5 × 10−14) and PR-negative disease (OR = 1.10, 95% CI = 1.06 to 1.15; P = .00002).
Conclusion
The rs13387042 is associated with both ER-positive and ER-negative breast cancer in European women. A recent genome-wide association study identified single-nucleotide polymorphism (SNP) 2q35-rs13387042 as a marker of susceptibility to estrogen receptor (ER)-positive breast cancer. We attempted to confirm this association using the Breast Cancer Association Consortium. 2q35-rs13387042 SNP was genotyped for 31 510 women with invasive breast cancer, 1101 women with ductal carcinoma in situ, and 35 969 female control subjects from 25 studies. Odds ratios (ORs) were estimated by logistic regression, adjusted for study. Heterogeneity in odds ratios by each of age, ethnicity, and study was assessed by fitting interaction terms. Heterogeneity by each of invasiveness, family history, bilaterality, and hormone receptor status was assessed by subclassifying case patients and applying polytomous logistic regression. All statistical tests were two-sided. We found strong evidence of association between rs13387042 and breast cancer in white women of European origin (per-allele OR = 1.12, 95% confidence interval [CI] = 1.09 to 1.15; P(trend) = 1.0 x 10(-19)). The odds ratio was lower than that previously reported (P = .02) and did not vary by age or ethnicity (all P > or = .2). However, it was higher when the analysis was restricted to case patients who were selected for a strong family history (P = .02). An association was observed for both ER-positive (OR = 1.14, 95% CI = 1.10 to 1.17; P = 10(-15)) and ER-negative disease (OR = 1.10, 95% CI = 1.04 to 1.15; P = .0003) and both progesterone receptor (PR)-positive (OR = 1.15, 95% CI = 1.11 to 1.19; P = 5 x 10(-14)) and PR-negative disease (OR = 1.10, 95% CI = 1.06 to 1.15; P = .00002). The rs13387042 is associated with both ER-positive and ER-negative breast cancer in European women. A recent genome-wide association study identified single-nucleotide polymorphism (SNP) 2q35-rs13387042 as a marker of susceptibility to estrogen receptor (ER)-positive breast cancer. We attempted to confirm this association using the Breast Cancer Association Consortium.BACKGROUNDA recent genome-wide association study identified single-nucleotide polymorphism (SNP) 2q35-rs13387042 as a marker of susceptibility to estrogen receptor (ER)-positive breast cancer. We attempted to confirm this association using the Breast Cancer Association Consortium.2q35-rs13387042 SNP was genotyped for 31 510 women with invasive breast cancer, 1101 women with ductal carcinoma in situ, and 35 969 female control subjects from 25 studies. Odds ratios (ORs) were estimated by logistic regression, adjusted for study. Heterogeneity in odds ratios by each of age, ethnicity, and study was assessed by fitting interaction terms. Heterogeneity by each of invasiveness, family history, bilaterality, and hormone receptor status was assessed by subclassifying case patients and applying polytomous logistic regression. All statistical tests were two-sided.METHODS2q35-rs13387042 SNP was genotyped for 31 510 women with invasive breast cancer, 1101 women with ductal carcinoma in situ, and 35 969 female control subjects from 25 studies. Odds ratios (ORs) were estimated by logistic regression, adjusted for study. Heterogeneity in odds ratios by each of age, ethnicity, and study was assessed by fitting interaction terms. Heterogeneity by each of invasiveness, family history, bilaterality, and hormone receptor status was assessed by subclassifying case patients and applying polytomous logistic regression. All statistical tests were two-sided.We found strong evidence of association between rs13387042 and breast cancer in white women of European origin (per-allele OR = 1.12, 95% confidence interval [CI] = 1.09 to 1.15; P(trend) = 1.0 x 10(-19)). The odds ratio was lower than that previously reported (P = .02) and did not vary by age or ethnicity (all P > or = .2). However, it was higher when the analysis was restricted to case patients who were selected for a strong family history (P = .02). An association was observed for both ER-positive (OR = 1.14, 95% CI = 1.10 to 1.17; P = 10(-15)) and ER-negative disease (OR = 1.10, 95% CI = 1.04 to 1.15; P = .0003) and both progesterone receptor (PR)-positive (OR = 1.15, 95% CI = 1.11 to 1.19; P = 5 x 10(-14)) and PR-negative disease (OR = 1.10, 95% CI = 1.06 to 1.15; P = .00002).RESULTSWe found strong evidence of association between rs13387042 and breast cancer in white women of European origin (per-allele OR = 1.12, 95% confidence interval [CI] = 1.09 to 1.15; P(trend) = 1.0 x 10(-19)). The odds ratio was lower than that previously reported (P = .02) and did not vary by age or ethnicity (all P > or = .2). However, it was higher when the analysis was restricted to case patients who were selected for a strong family history (P = .02). An association was observed for both ER-positive (OR = 1.14, 95% CI = 1.10 to 1.17; P = 10(-15)) and ER-negative disease (OR = 1.10, 95% CI = 1.04 to 1.15; P = .0003) and both progesterone receptor (PR)-positive (OR = 1.15, 95% CI = 1.11 to 1.19; P = 5 x 10(-14)) and PR-negative disease (OR = 1.10, 95% CI = 1.06 to 1.15; P = .00002).The rs13387042 is associated with both ER-positive and ER-negative breast cancer in European women.CONCLUSIONThe rs13387042 is associated with both ER-positive and ER-negative breast cancer in European women. Background A recent genome-wide association study identified single-nucleotide polymorphism (SNP) 2q35-rs13387042 as a marker of susceptibility to estrogen receptor (ER)–positive breast cancer. We attempted to confirm this association using the Breast Cancer Association Consortium. Methods 2q35-rs13387042 SNP was genotyped for 31 510 women with invasive breast cancer, 1101 women with ductal carcinoma in situ, and 35 969 female control subjects from 25 studies. Odds ratios (ORs) were estimated by logistic regression, adjusted for study. Heterogeneity in odds ratios by each of age, ethnicity, and study was assessed by fitting interaction terms. Heterogeneity by each of invasiveness, family history, bilaterality, and hormone receptor status was assessed by subclassifying case patients and applying polytomous logistic regression. All statistical tests were two-sided. Results We found strong evidence of association between rs13387042 and breast cancer in white women of European origin (per-allele OR = 1.12, 95% confidence interval [CI] = 1.09 to 1.15; Ptrend = 1.0 × 10−19). The odds ratio was lower than that previously reported (P = .02) and did not vary by age or ethnicity (all P ≥ .2). However, it was higher when the analysis was restricted to case patients who were selected for a strong family history (P = .02). An association was observed for both ER-positive (OR = 1.14, 95% CI = 1.10 to 1.17; P = 10−15) and ER-negative disease (OR = 1.10, 95% CI = 1.04 to 1.15; P = .0003) and both progesterone receptor (PR)–positive (OR = 1.15, 95% CI = 1.11 to 1.19; P = 5 × 10−14) and PR-negative disease (OR = 1.10, 95% CI = 1.06 to 1.15; P = .00002). Conclusion The rs13387042 is associated with both ER-positive and ER-negative breast cancer in European women. Background A recent genome-wide association study identified single-nucleotide polymorphism (SNP) 2q35-rs13387042 as a marker of susceptibility to estrogen receptor (ER)-positive breast cancer. We attempted to confirm this association using the Breast Cancer Association Consortium.Methods 2q35-rs13387042 SNP was genotyped for 31 510 women with invasive breast cancer, 1101 women with ductal carcinoma in situ, and 35 969 female control subjects from 25 studies. Odds ratios (ORs) were estimated by logistic regression, adjusted for study. Heterogeneity in odds ratios by each of age, ethnicity, and study was assessed by fitting interaction terms. Heterogeneity by each of invasiveness, family history, bilaterality, and hormone receptor status was assessed by subclassifying case patients and applying polytomous logistic regression. All statistical tests were two-sided.Results We found strong evidence of association between rs13387042 and breast cancer in white women of European origin (per-allele OR = 1.12, 95% confidence interval [CI] = 1.09 to 1.15; Ptrend = 1.0 10-19 ). The odds ratio was lower than that previously reported (P = .02) and did not vary by age or ethnicity (all P greater than or equal to .2). However, it was higher when the analysis was restricted to case patients who were selected for a strong family history (P = .02). An association was observed for both ER-positive (OR = 1.14, 95% CI = 1.10 to 1.17; P = 10-15 ) and ER-negative disease (OR = 1.10, 95% CI = 1.04 to 1.15; P = .0003) and both progesterone receptor (PR)-positive (OR = 1.15, 95% CI = 1.11 to 1.19; P = 5 10-14 ) and PR-negative disease (OR = 1.10, 95% CI = 1.06 to 1.15; P = .00002).Conclusion The rs13387042 is associated with both ER-positive and ER-negative breast cancer in European women. Background: A recent genome-wide association study identified single-nucleotide polymorphism (SNP) 2q35-rs13387042 as a marker of susceptibility to estrogen receptor (ER)-positive breast cancer. We attempted to confirm this association using the Breast Cancer Association Consortium. Methods: 2q35-rs13387042 SNP was genotyped for 31 510 women with invasive breast cancer, 1101 women with ductal carcinoma in situ, and 35 969 female control subjects from 25 studies. Odds ratios (ORs) were estimated by logistic regression, adjusted for study. Heterogeneity in odds ratios by each of age, ethnicity, and study was assessed by fitting interaction terms. Heterogeneity by each of invasiveness, family history, bilaterality, and hormone receptor status was assessed by subclassifying case patients and applying polytomous logistic regression. All statistical tests were two-sided. Results: We found strong evidence of association between rs13387042 and breast cancer in white women of European origin (per-allele OR = 1.12, 95% confidence interval [CI] = 1.09 to 1.15; Ptrend = 1.0 × 10-19 ). The odds ratio was lower than that previously reported (P = .02) and did not vary by age or ethnicity (all P ≥ .2). However, it was higher when the analysis was restricted to case patients who were selected for a strong family history (P = .02). An association was observed for both ER-positive (OR = 1.14, 95% CI = 1.10 to 1.17; P = 10-15 ) and ER-negative disease (OR = 1.10, 95% CI = 1.04 to 1.15; P = .0003) and both progesterone receptor (PR)-positive (OR = 1.15, 95% CI = 1.11 to 1.19; P = 5 × 10-14 ) and PR-negative disease (OR = 1.10, 95% CI = 1.06 to 1.15; P = .00002). Conclusion: The rs13387042 is associated with both ER-positive and ER-negative breast cancer in European women. [PUBLICATION ABSTRACT] |
| Author | Schürmann, Peter Bartram, Claus R. Liu, Jianjun Maranian, Melanie Elliott, Graeme Beesley, Jonathan Hillemanns, Peter Hopper, John L. Zalutsky, Iosif V. Yoo, Keun-Young Blomqvist, Carl Peto, Julian Yu, Jyh-Cherng Johnson, Nichola Anton-Culver, Hoda Fletcher, Olivia Milne, Roger L. Burwinkel, Barbara Turnbull, Clare Morrison, Jonathan Kang, Daehee van Asperen, Christie J. Wang-Gohrke, Shan Chenevix-Trench, Georgia Shen, Chen-Yang Platte, Radka Easton, Douglas F. Justenhoven, Christina Arias, José Ignacio Wang, Xianshu Chen, Sou-Tong Beckmann, Matthias W. Hall, Per Couch, Fergus J. Meindl, Alfons Khusnutdinova, Elza Benítez, Javier Haas, Susanne Smith, Letitia Fasching, Peter A. Bermisheva, Marina Humphreys, Manjeet K. Ko, Yon-Dschun Heikkinen, Tuomas Dörk, Thilo Li, Yuqing García-Closas, Montserrat Baglietto, Laura Dunning, Alison M. Giles, Graham G. Olson, Janet E. dos Santos Silva, Isabel Aittomäki, Kristiina Pharoah, Paul D. P. Kataja, Vesa English, Dallas R. Mannermaa, Arto Bogdanova, Natalia V. Tollenaar, Rob A. E. M. Bojesen, Stig E. Reed, |
| AuthorAffiliation | Affiliations of authors: Genetic and Molecular Epidemiology Group (RLM) and Human Genetics Group (JBe), Spanish National Cancer Research Centre [CNIO], Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras [CIBERER], Madrid, Spain (JBe); Department of Obstetrics and Gynecology (HN, TH), Department of Clinical Genetics (KA), and Department of Oncology (CB), Helsinki University Central Hospital, Helsinki, Finland; Servicio de Cirugía General y Especialidades, Hospital Monte Naranco, Oviedo, Spain (JIA); Servicio de Oncología Médica, Hospital Universitario La Paz, Madrid, Spain (MPZ); Department of Obstetrics and Gynecology (BB) and Institute of Human Genetics (CRB), University of Heidelberg, Heidelberg, Germany; Molecular Epidemiology Group (BB) and Division of Cancer Epidemiology (JC-C), German Cancer Research Center [DKFZ]), Heidelberg, Germany; Department of Gynaecology and Obstetrics, Technical University of Munich, Munich, Germany (AMe); Department of Gynaeco |
| AuthorAffiliation_xml | – name: Affiliations of authors: Genetic and Molecular Epidemiology Group (RLM) and Human Genetics Group (JBe), Spanish National Cancer Research Centre [CNIO], Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras [CIBERER], Madrid, Spain (JBe); Department of Obstetrics and Gynecology (HN, TH), Department of Clinical Genetics (KA), and Department of Oncology (CB), Helsinki University Central Hospital, Helsinki, Finland; Servicio de Cirugía General y Especialidades, Hospital Monte Naranco, Oviedo, Spain (JIA); Servicio de Oncología Médica, Hospital Universitario La Paz, Madrid, Spain (MPZ); Department of Obstetrics and Gynecology (BB) and Institute of Human Genetics (CRB), University of Heidelberg, Heidelberg, Germany; Molecular Epidemiology Group (BB) and Division of Cancer Epidemiology (JC-C), German Cancer Research Center [DKFZ]), Heidelberg, Germany; Department of Gynaecology and Obstetrics, Technical University of Munich, Munich, Germany (AMe); Department of Gynaecology and Obstetrics, Clinical Center University of Cologne, Köln, Germany (RKS); Institute for Cancer Studies (AC, IB, GE) and Academic Unit of Surgical Oncology (MWRR), Sheffield University Medical School, Sheffield, UK; Centre for Molecular, Environmental, Genetic and Analytic Epidemiology (JLH, DRE) and Department of Pathology (MCS, LS), University of Melbourne, Victoria, Australia; Department of Laboratory Medicine and Pathology (FJC, XW) and Department of Health Sciences Research (JEO, ZF), Mayo Clinic, Rochester, MN; Department of Obstetrics and Gynaecology (TD, PS, PHi, NVB, MBe) and Department of Radiation Oncology (MBr, NVB), Hannover Medical School, Hannover, Germany; Department of Human Genetics (PD), Department of Pathology (PD), Department of Clinical Genetics (CJvA), and Department of Surgery (RAEMT), Leiden University Medical Centre, Leiden, the Netherlands; Department of Medical Oncology, Rotterdam Family Cancer Clinic, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, the Netherlands (CS); Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden (PHa, KC); Human Genetics Laboratory, Genome Institute of Singapore, Singapore (JLi, YL); Department of Oncology (SA, AMD, MM, PDPP), Department of Public Health and Primary Care (PDPP), University of Cambridge, Cambridge, UK; Division of Genetics and Population Health (GC-T, JBee, ABS), Queensland Institute of Medical Research (AOCS), Brisbane, Australia; Peter MacCallum Cancer Center, Melbourne, Australia (kConFab, AOCS); N.N. Alexandrov Research Institute of Oncology and Medical Radiology, Minsk, Belarus (NVB, NNA, IVZ); Department of Epidemiology, University of California Irvine, Irvine, CA (HA-C, AZ); Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany (HB, CJ); University of Tübingen, Tübingen, Germany (HB, CJ); Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany (Y-DK); Institute of Pathology, University of Bonn, Bonn, Germany (SHa); University Breast Center (PAF, RS, MWB) and Institute of Human Genetics (ABE), University Hospital Erlangen, Erlangen, Germany; Department of Gynecology and Obstetrics, David Geffen School of Medicine, Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, CA (PAF); Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Australia (GGG, GS, LB); Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK (OF, NJ); Cancer Research UK Epidemiology and Genetics Group, London School of Hygiene and Tropical Medicine, London, UK (OF, IdSS, JP); Section of Cancer Genetics (CT, SHi, AR, NR), Institute of Cancer Research (JP), Sutton, Surrey, UK; Department of Clinical Biochemistry and Department of Breast Surgery, Herlev University Hospital, University of Copenhagen, Denmark (BGN, SEB, HF); Seoul National University College of Medicine, Seoul, Korea (DK, K-YY, D-YN); Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Kuopio (AMa, V-MK); Department of Oncology and Department of Pathology, University Hospital of Kuopio and Biocenter Kuopio, Kuopio, Finland (VK); Department of Oncology, Vaasa Central Hospital, Vaasa, Finland (VK); Division of Cancer Epidemiology and Genetics (MG-C, SC) and Hormonal and Reproductive Epidemiology Branch (LAB), National Cancer Institute, Rockville, MD; Department of Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center & Institute of Oncology, Warsaw, Poland (JLis); Department of Gynecology and Obstetrics, Ulm Medical School, Ulm, Germany (SW-G); Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan (C-YS, H-CW); Department of Surgery, Tri-Service General Hospital, Taipei, Taiwan (J-CY); Department of Surgery, Changhua Christian Hospital, Changhua, Taiwan (S-TC); Institute of Biochemistry and Genetics, Ufa Scientific Center of Russian Academy of Sciences, Ufa, Russia (MBe, EK); Department of Medical Genetics, Yakut Research Center of Russian Academy of Medical Sciences, Yakutsk, Russia (TN); Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK (MKH, JM, RP, DFE |
| Author_xml | – sequence: 1 givenname: Roger L. surname: Milne fullname: Milne, Roger L. organization: Correspondence to: Roger L. Milne, PhD, Genetic and Molecular Epidemiology Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), C/ Melchor Fernández Almagro, 3, 29029, Madrid, Spain (e-mail: rmilne@cnio.es) – sequence: 2 givenname: Javier surname: Benítez fullname: Benítez, Javier – sequence: 3 givenname: Heli surname: Nevanlinna fullname: Nevanlinna, Heli – sequence: 4 givenname: Tuomas surname: Heikkinen fullname: Heikkinen, Tuomas – sequence: 5 givenname: Kristiina surname: Aittomäki fullname: Aittomäki, Kristiina – sequence: 6 givenname: Carl surname: Blomqvist fullname: Blomqvist, Carl – sequence: 7 givenname: José Ignacio surname: Arias fullname: Arias, José Ignacio – sequence: 8 givenname: M. Pilar surname: Zamora fullname: Zamora, M. Pilar – sequence: 9 givenname: Barbara surname: Burwinkel fullname: Burwinkel, Barbara – sequence: 10 givenname: Claus R. surname: Bartram fullname: Bartram, Claus R. – sequence: 11 givenname: Alfons surname: Meindl fullname: Meindl, Alfons – sequence: 12 givenname: Rita K. surname: Schmutzler fullname: Schmutzler, Rita K. – sequence: 13 givenname: Angela surname: Cox fullname: Cox, Angela – sequence: 14 givenname: Ian surname: Brock fullname: Brock, Ian – sequence: 15 givenname: Graeme surname: Elliott fullname: Elliott, Graeme – sequence: 16 givenname: Malcolm W. R. surname: Reed fullname: Reed, Malcolm W. R. – sequence: 17 givenname: Melissa C. surname: Southey fullname: Southey, Melissa C. – sequence: 18 givenname: Letitia surname: Smith fullname: Smith, Letitia – sequence: 19 givenname: Amanda B. surname: Spurdle fullname: Spurdle, Amanda B. – sequence: 20 givenname: John L. surname: Hopper fullname: Hopper, John L. – sequence: 21 givenname: Fergus J. surname: Couch fullname: Couch, Fergus J. – sequence: 22 givenname: Janet E. surname: Olson fullname: Olson, Janet E. – sequence: 23 givenname: Xianshu surname: Wang fullname: Wang, Xianshu – sequence: 24 givenname: Zachary surname: Fredericksen fullname: Fredericksen, Zachary – sequence: 25 givenname: Peter surname: Schürmann fullname: Schürmann, Peter – sequence: 26 givenname: Michael surname: Bremer fullname: Bremer, Michael – sequence: 27 givenname: Peter surname: Hillemanns fullname: Hillemanns, Peter – sequence: 28 givenname: Thilo surname: Dörk fullname: Dörk, Thilo – sequence: 29 givenname: Peter surname: Devilee fullname: Devilee, Peter – sequence: 30 givenname: Christie J. surname: van Asperen fullname: van Asperen, Christie J. – sequence: 31 givenname: Rob A. E. M. surname: Tollenaar fullname: Tollenaar, Rob A. E. M. – sequence: 32 givenname: Caroline surname: Seynaeve fullname: Seynaeve, Caroline – sequence: 33 givenname: Per surname: Hall fullname: Hall, Per – sequence: 34 givenname: Kamila surname: Czene fullname: Czene, Kamila – sequence: 35 givenname: Jianjun surname: Liu fullname: Liu, Jianjun – sequence: 36 givenname: Yuqing surname: Li fullname: Li, Yuqing – sequence: 37 givenname: Shahana surname: Ahmed fullname: Ahmed, Shahana – sequence: 38 givenname: Alison M. surname: Dunning fullname: Dunning, Alison M. – sequence: 39 givenname: Melanie surname: Maranian fullname: Maranian, Melanie – sequence: 40 givenname: Paul D. P. surname: Pharoah fullname: Pharoah, Paul D. P. – sequence: 41 givenname: Georgia surname: Chenevix-Trench fullname: Chenevix-Trench, Georgia – sequence: 42 givenname: Jonathan surname: Beesley fullname: Beesley, Jonathan – sequence: 43 givenname: Natalia V. surname: Bogdanova fullname: Bogdanova, Natalia V. – sequence: 44 givenname: Natalia N. surname: Antonenkova fullname: Antonenkova, Natalia N. – sequence: 45 givenname: Iosif V. surname: Zalutsky fullname: Zalutsky, Iosif V. – sequence: 46 givenname: Hoda surname: Anton-Culver fullname: Anton-Culver, Hoda – sequence: 47 givenname: Argyrios surname: Ziogas fullname: Ziogas, Argyrios – sequence: 48 givenname: Hiltrud surname: Brauch fullname: Brauch, Hiltrud – sequence: 49 givenname: Christina surname: Justenhoven fullname: Justenhoven, Christina – sequence: 50 givenname: Yon-Dschun surname: Ko fullname: Ko, Yon-Dschun – sequence: 51 givenname: Susanne surname: Haas fullname: Haas, Susanne – sequence: 52 givenname: Peter A. surname: Fasching fullname: Fasching, Peter A. – sequence: 53 givenname: Reiner surname: Strick fullname: Strick, Reiner – sequence: 54 givenname: Arif B. surname: Ekici fullname: Ekici, Arif B. – sequence: 55 givenname: Matthias W. surname: Beckmann fullname: Beckmann, Matthias W. – sequence: 56 givenname: Graham G. surname: Giles fullname: Giles, Graham G. – sequence: 57 givenname: Gianluca surname: Severi fullname: Severi, Gianluca – sequence: 58 givenname: Laura surname: Baglietto fullname: Baglietto, Laura – sequence: 59 givenname: Dallas R. surname: English fullname: English, Dallas R. – sequence: 60 givenname: Olivia surname: Fletcher fullname: Fletcher, Olivia – sequence: 61 givenname: Nichola surname: Johnson fullname: Johnson, Nichola – sequence: 62 givenname: Isabel surname: dos Santos Silva fullname: dos Santos Silva, Isabel – sequence: 63 givenname: Julian surname: Peto fullname: Peto, Julian – sequence: 64 givenname: Clare surname: Turnbull fullname: Turnbull, Clare – sequence: 65 givenname: Sarah surname: Hines fullname: Hines, Sarah – sequence: 66 givenname: Anthony surname: Renwick fullname: Renwick, Anthony – sequence: 67 givenname: Nazneen surname: Rahman fullname: Rahman, Nazneen – sequence: 68 givenname: Børge G. surname: Nordestgaard fullname: Nordestgaard, Børge G. – sequence: 69 givenname: Stig E. surname: Bojesen fullname: Bojesen, Stig E. – sequence: 70 givenname: Henrik surname: Flyger fullname: Flyger, Henrik – sequence: 71 givenname: Daehee surname: Kang fullname: Kang, Daehee – sequence: 72 givenname: Keun-Young surname: Yoo fullname: Yoo, Keun-Young – sequence: 73 givenname: Dong-Young surname: Noh fullname: Noh, Dong-Young – sequence: 74 givenname: Arto surname: Mannermaa fullname: Mannermaa, Arto – sequence: 75 givenname: Vesa surname: Kataja fullname: Kataja, Vesa – sequence: 76 givenname: Veli-Matti surname: Kosma fullname: Kosma, Veli-Matti – sequence: 77 givenname: Montserrat surname: García-Closas fullname: García-Closas, Montserrat – sequence: 78 givenname: Stephen surname: Chanock fullname: Chanock, Stephen – sequence: 79 givenname: Jolanta surname: Lissowska fullname: Lissowska, Jolanta – sequence: 80 givenname: Louise A. surname: Brinton fullname: Brinton, Louise A. – sequence: 81 givenname: Jenny surname: Chang-Claude fullname: Chang-Claude, Jenny – sequence: 82 givenname: Shan surname: Wang-Gohrke fullname: Wang-Gohrke, Shan – sequence: 83 givenname: Chen-Yang surname: Shen fullname: Shen, Chen-Yang – sequence: 84 givenname: Hui-Chun surname: Wang fullname: Wang, Hui-Chun – sequence: 85 givenname: Jyh-Cherng surname: Yu fullname: Yu, Jyh-Cherng – sequence: 86 givenname: Sou-Tong surname: Chen fullname: Chen, Sou-Tong – sequence: 87 givenname: Marina surname: Bermisheva fullname: Bermisheva, Marina – sequence: 88 givenname: Tatjana surname: Nikolaeva fullname: Nikolaeva, Tatjana – sequence: 89 givenname: Elza surname: Khusnutdinova fullname: Khusnutdinova, Elza – sequence: 90 givenname: Manjeet K. surname: Humphreys fullname: Humphreys, Manjeet K. – sequence: 91 givenname: Jonathan surname: Morrison fullname: Morrison, Jonathan – sequence: 92 givenname: Radka surname: Platte fullname: Platte, Radka – sequence: 93 givenname: Douglas F. surname: Easton fullname: Easton, Douglas F. |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21718928$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/19567422$$D View this record in MEDLINE/PubMed http://kipublications.ki.se/Default.aspx?queryparsed=id:119100575$$DView record from Swedish Publication Index |
| BookMark | eNqFksFu1DAQhiNURLeFE3cUIcEFhdqTOLYvSHRVKFJV2gIS4mJ5ndmtd7NxaictvfEOvCFPgrcbFloJ1Rd7Zr75NZ6ZnWSrcQ0myVNKXlMi8715Y-xeNW9pyR8kI1qUJANK2FYyIgR4JgQvtpOdEOYkHgnFo2SbSlbyAmCUXJ3ZsEjdND0InXczbNIzNNh2zv_68fPEBdvZS0x1U6XRPsaZvrH3PerQpWPdGPQ30U-2mdW4YnpTo-tshemJq6-XzrfnNixTuMhZ5gPNc8FJAY-Th1NdB3wy3LvJl3cHn8eH2dHH9x_Gb48yUxaky6SWFUFGxMRwWVZa8imJDi0ZE1NayIqB4ALKXKMmpazKoqBodIGlzoHCJN9NsrVuuMK2n6jW26X218ppqwbXIr5QMcYBWOTfrPkYWWJlsOm8rm-l3Y409lzN3KUCDoVgJAq8HAS8u-gxdGppg8G61g26PqjYd0ko0HtBIEDjWSk-vwPOXe-b2DUFQKSMVfMIPfu37k3BfyYdgRcDoIPR9dTH2dmw4YByKiSIyL1ac8a7EDxO_0oRtdo3tdo3td63SNM7tLFd3BG3ao6t_5MzfNz17T3iw-xs6PD7BtV-EbuYc6YOv35Tp_vH41MiQIn8NxD3-OA |
| CODEN | JNCIEQ |
| CitedBy_id | crossref_primary_10_1093_hmg_ddw223 crossref_primary_10_1111_j_1399_0004_2012_01859_x crossref_primary_10_1093_annonc_mdq596 crossref_primary_10_1111_j_1365_2796_2011_02502_x crossref_primary_10_1111_j_1399_0004_2010_01473_x crossref_primary_10_1371_journal_pone_0069056 crossref_primary_10_1016_j_clbc_2024_03_009 crossref_primary_10_1007_s10552_010_9717_0 crossref_primary_10_1007_s10911_011_9213_5 crossref_primary_10_1186_bcr3057 crossref_primary_10_1186_s12859_021_04147_y crossref_primary_10_1007_s11033_022_07195_6 crossref_primary_10_1038_bjc_2011_118 crossref_primary_10_1186_bcr3052 crossref_primary_10_1371_journal_pone_0066979 crossref_primary_10_1002_humu_21134 crossref_primary_10_1038_ng_586 crossref_primary_10_1039_c0ib00094a crossref_primary_10_1007_s10549_010_1215_2 crossref_primary_10_1093_annonc_mdq660 crossref_primary_10_1093_hmg_ddu311 crossref_primary_10_1093_hmg_ddr367 crossref_primary_10_1093_hmg_ddr368 crossref_primary_10_1186_1471_2458_13_114 crossref_primary_10_1093_hmg_ddt581 crossref_primary_10_1111_j_1349_7006_2011_02047_x crossref_primary_10_1038_jhg_2016_97 crossref_primary_10_1016_j_molonc_2010_04_011 crossref_primary_10_1158_1055_9965_EPI_10_0054 crossref_primary_10_1186_1471_2407_13_510 crossref_primary_10_1002_jso_24834 crossref_primary_10_1093_jnci_djr265 crossref_primary_10_1007_s11033_014_3236_0 crossref_primary_10_1007_s13669_012_0034_3 crossref_primary_10_1186_bcr2797 crossref_primary_10_1186_bcr2476 crossref_primary_10_4103_tcmj_tcmj_45_19 crossref_primary_10_1093_hmg_ddu223 crossref_primary_10_1007_s10549_011_1663_3 crossref_primary_10_1093_hmg_ddp372 crossref_primary_10_1093_carcin_bgr214 crossref_primary_10_1002_humu_22089 crossref_primary_10_1016_j_cancergencyto_2010_01_020 crossref_primary_10_1158_1940_6207_CAPR_12_0346_T crossref_primary_10_1371_journal_pone_0216997 crossref_primary_10_1038_ncomms5999 crossref_primary_10_1007_s10549_010_1292_2 crossref_primary_10_1371_journal_pgen_1002290 crossref_primary_10_1158_1055_9965_EPI_12_0526 crossref_primary_10_1186_bcr3591 crossref_primary_10_18632_oncotarget_13168 crossref_primary_10_1016_j_gde_2010_03_012 crossref_primary_10_1016_j_gde_2010_03_010 crossref_primary_10_1371_journal_pone_0035706 crossref_primary_10_1093_hmg_dds159 crossref_primary_10_1186_bcr2817 crossref_primary_10_3389_fendo_2022_983793 crossref_primary_10_1158_1055_9965_EPI_11_0719 crossref_primary_10_1007_s00439_011_1030_9 crossref_primary_10_1016_j_tig_2009_12_008 crossref_primary_10_1093_ije_dyv118 crossref_primary_10_1371_journal_pgen_1003284 crossref_primary_10_1111_j_1349_7006_2010_01496_x crossref_primary_10_1186_bcr3101 crossref_primary_10_1200_JCO_2012_41_7469 crossref_primary_10_1186_1897_4287_11_12 crossref_primary_10_1002_cncr_27515 crossref_primary_10_1093_hmg_ddr228 crossref_primary_10_1002_humu_22159 crossref_primary_10_1186_bcr2414 crossref_primary_10_1371_journal_pone_0074765 crossref_primary_10_1038_bjc_2011_461 crossref_primary_10_1093_jnci_djp184 |
| Cites_doi | 10.1038/ng2064 10.1002/gepi.10261 10.1038/ng.131 10.1038/ng2075 10.1038/nature05887 10.1371/journal.pgen.1000054 10.1093/jnci/djm270 |
| ContentType | Journal Article |
| Contributor | Moreno, Tais Zatonski, Witold Cross, Simon Connley, Dan Krol-Warmerdam, E Bowtell, D Pita, Guillermo Harth, Volker Webb, P Cramp, Helen Brüning, Thomas Angelakos, Maggie Balasubramanian, Sabapathy Dite, Gillian Tchatchou, Sandrine Eilber, Ursula Hayward, N Menendez, Primitiva Karstens, Johann H Green, A deFazio, A Alonso, Charo Chenevix-Trench, G Jäntti, R N Hanna Chao, Pei Szeszenia-Dabrowska, Neonila Sherman, Mark Niedermayr, Eveline Myöhänen, Eija Thorne, Heather Gertig, D Pesch, Beate Aaltonen, Kirsimari González-Neira, Anna Maskiell, Judi Koehler, Tanja Peplonska, Beata Whiteman, D Parsons, P Huijts, P E A Blom, J Hamann, Ute |
| Contributor_xml | – sequence: 1 givenname: Primitiva surname: Menendez fullname: Menendez, Primitiva – sequence: 2 givenname: Anna surname: González-Neira fullname: González-Neira, Anna – sequence: 3 givenname: Charo surname: Alonso fullname: Alonso, Charo – sequence: 4 givenname: Tais surname: Moreno fullname: Moreno, Tais – sequence: 5 givenname: Guillermo surname: Pita fullname: Pita, Guillermo – sequence: 6 givenname: Kirsimari surname: Aaltonen fullname: Aaltonen, Kirsimari – sequence: 7 givenname: R N Hanna surname: Jäntti fullname: Jäntti, R N Hanna – sequence: 8 givenname: Sandrine surname: Tchatchou fullname: Tchatchou, Sandrine – sequence: 9 givenname: Sabapathy surname: Balasubramanian fullname: Balasubramanian, Sabapathy – sequence: 10 givenname: Simon surname: Cross fullname: Cross, Simon – sequence: 11 givenname: Helen surname: Cramp fullname: Cramp, Helen – sequence: 12 givenname: Dan surname: Connley fullname: Connley, Dan – sequence: 13 givenname: Maggie surname: Angelakos fullname: Angelakos, Maggie – sequence: 14 givenname: Judi surname: Maskiell fullname: Maskiell, Judi – sequence: 15 givenname: Gillian surname: Dite fullname: Dite, Gillian – sequence: 16 givenname: Johann H surname: Karstens fullname: Karstens, Johann H – sequence: 17 givenname: P E A surname: Huijts fullname: Huijts, P E A – sequence: 18 givenname: E surname: Krol-Warmerdam fullname: Krol-Warmerdam, E – sequence: 19 givenname: J surname: Blom fullname: Blom, J – sequence: 20 givenname: Heather surname: Thorne fullname: Thorne, Heather – sequence: 21 givenname: Eveline surname: Niedermayr fullname: Niedermayr, Eveline – sequence: 22 givenname: D surname: Bowtell fullname: Bowtell, D – sequence: 23 givenname: G surname: Chenevix-Trench fullname: Chenevix-Trench, G – sequence: 24 givenname: A surname: deFazio fullname: deFazio, A – sequence: 25 givenname: D surname: Gertig fullname: Gertig, D – sequence: 26 givenname: A surname: Green fullname: Green, A – sequence: 27 givenname: P surname: Webb fullname: Webb, P – sequence: 28 givenname: P surname: Parsons fullname: Parsons, P – sequence: 29 givenname: N surname: Hayward fullname: Hayward, N – sequence: 30 givenname: D surname: Whiteman fullname: Whiteman, D – sequence: 31 givenname: Ute surname: Hamann fullname: Hamann, Ute – sequence: 32 givenname: Beate surname: Pesch fullname: Pesch, Beate – sequence: 33 givenname: Volker surname: Harth fullname: Harth, Volker – sequence: 34 givenname: Thomas surname: Brüning fullname: Brüning, Thomas – sequence: 35 givenname: Eija surname: Myöhänen fullname: Myöhänen, Eija – sequence: 36 givenname: Neonila surname: Szeszenia-Dabrowska fullname: Szeszenia-Dabrowska, Neonila – sequence: 37 givenname: Beata surname: Peplonska fullname: Peplonska, Beata – sequence: 38 givenname: Witold surname: Zatonski fullname: Zatonski, Witold – sequence: 39 givenname: Mark surname: Sherman fullname: Sherman, Mark – sequence: 40 givenname: Pei surname: Chao fullname: Chao, Pei – sequence: 41 givenname: Ursula surname: Eilber fullname: Eilber, Ursula – sequence: 42 givenname: Tanja surname: Koehler fullname: Koehler, Tanja |
| Copyright | The Author 2009. Published by Oxford University Press. 2009 2009 INIST-CNRS The Author 2009. Published by Oxford University Press. |
| Copyright_xml | – notice: The Author 2009. Published by Oxford University Press. 2009 – notice: 2009 INIST-CNRS – notice: The Author 2009. Published by Oxford University Press. |
| CorporateAuthor | AOCS Group on behalf of the Breast Cancer Association Consortium kConFab Investigators Breast Cancer Association Consortium |
| CorporateAuthor_xml | – name: kConFab Investigators – name: AOCS Group – name: on behalf of the Breast Cancer Association Consortium – name: Breast Cancer Association Consortium |
| DBID | BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7TO 7U7 7U9 C1K H94 K9. NAPCQ 7TM 7U1 7X8 5PM ADTPV AOWAS |
| DOI | 10.1093/jnci/djp167 |
| DatabaseName | Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Oncogenes and Growth Factors Abstracts Toxicology Abstracts Virology and AIDS Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Nucleic Acids Abstracts Risk Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) SwePub SwePub Articles |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Nursing & Allied Health Premium Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts Toxicology Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Environmental Sciences and Pollution Management Risk Abstracts Nucleic Acids Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Risk Abstracts Nursing & Allied Health Premium |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1460-2105 |
| EndPage | 1018 |
| ExternalDocumentID | oai_swepub_ki_se_557225 PMC2724850 1790304051 19567422 21718928 10_1093_jnci_djp167 10.1093/jnci/djp167 ark_67375_HXZ_QBNCQ082_8 |
| Genre | Research Support, U.S. Gov't, Non-P.H.S Multicenter Study Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GeographicLocations | United States North America America |
| GrantInformation_xml | – fundername: Cancer Research UK grantid: A10119 – fundername: Cancer Research UK grantid: A10124 – fundername: Cancer Research UK grantid: 10119 – fundername: Cancer Research UK grantid: C1287/A7497 – fundername: Wellcome Trust grantid: 068545/Z/02 – fundername: NCI NIH HHS grantid: CA-95-011 – fundername: NCI NIH HHS grantid: CA92044 – fundername: NCI NIH HHS grantid: CA69417 – fundername: Intramural NIH HHS – fundername: Cancer Research UK grantid: 10124 |
| GroupedDBID | --- -DD -E4 -~X .2P .55 .GJ .I3 .XZ .ZR 08P 0R~ 186 1TH 29L 2QL 2WC 354 3O- 4.4 482 48X 53G 5GY 5RE 5VS 5WD 70D 8WZ 96U A6W AABZA AACZT AAGKA AAHTB AAJKP AAJQQ AAKAS AAMVS AAOGV AAPGJ AAPNW AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP AAWDT AAWTL ABCQX ABDFA ABEFU ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABNGD ABNHQ ABNKS ABOCM ABPEJ ABPMR ABPPZ ABPTD ABQLI ABQNK ABSMQ ABVGC ABXVV ABZBJ ACBMB ACFRR ACGFO ACGFS ACGOD ACKOT ACNCT ACPQN ACPRK ACUFI ACUKT ACUTJ ACUTO ACVCV ACYHN ACZBC ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADIPN ADMTO ADNBA ADOCK ADQBN ADRTK ADVEK ADXHL ADYVW ADZCM AEGPL AEHUL AEJOX AEKPW AEKSI AEMDU AEMQT AENZO AEPUE AETBJ AETEA AEWNT AFAZI AFCHL AFFNX AFFQV AFFZL AFIYH AFOFC AFRAH AFSHK AFXAL AFYAG AGINJ AGKEF AGKRT AGMDO AGNAY AGORE AGQPQ AGSYK AGUTN AHGBF AHMBA AHMMS AHXPO AI. AIAGR AIJHB AJBYB AJDVS AJEEA AJNCP ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APJGH APWMN AQDSO AQKUS ASPBG ATGXG ATTQO AVNTJ AVWKF AZFZN BAWUL BAYMD BCRHZ BEYMZ BKOMP BSCLL BTRTY BVRKM BZKNY C45 CAG CDBKE COF CS3 CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBS EE~ EIHJH EJD EMOBN ENERS F5P F8P F9B FA8 FECEO FEDTE FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GOZPB GRPMH GX1 H13 H5~ HAR HVGLF HW0 HZ~ IH2 IOX J21 J5H JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B LXL LXN LXY M-Z MBLQV MHKGH ML0 MVM N9A NGC NOMLY NOYVH NTWIH NU- NVLIB O0~ OAUYM OAWHX OBFPC OBH OCB OCZFY ODMLO ODZKP OGEVE OHH OJQWA OJZSN OK1 OPAEJ OVD OWPYF O~Y P2P PAFKI PB- PEELM PQQKQ Q.- Q1. Q5Y QBD R44 RD5 RNI RNS ROL ROX ROZ RUSNO RW1 RXO RZF RZO TCURE TEORI TJX TMA TR2 TWZ UDS UPT VH1 VVN W8F WH7 WOQ X7H X7M XJT Y6R YAYTL YHZ YKOAZ YQT YR5 YXANX ZKX ZRR ZY1 ~91 ~H1 ~X8 AASNB ABQTQ ADJQC ADRIX ADZXQ M49 RHF AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7TO 7U7 7U9 C1K H94 K9. NAPCQ 7TM 7U1 7X8 5PM ADTPV AOWAS |
| ID | FETCH-LOGICAL-c640t-9a9d0e508bc796da97f0d0ea9558f149d52878263aea069d6441eca4e6a3212b3 |
| ISSN | 0027-8874 1460-2105 |
| IngestDate | Mon Aug 25 03:39:36 EDT 2025 Thu Aug 21 14:32:28 EDT 2025 Fri Jul 11 03:19:32 EDT 2025 Fri Jul 11 05:20:01 EDT 2025 Mon Jun 30 10:42:42 EDT 2025 Mon Jul 21 06:03:54 EDT 2025 Mon Jul 21 09:14:43 EDT 2025 Thu Apr 24 22:56:13 EDT 2025 Tue Jul 01 01:42:07 EDT 2025 Wed Sep 11 04:51:27 EDT 2024 Tue Aug 05 16:47:13 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 14 |
| Keywords | Human Estrogen receptor Breast disease Genetic variability Chromosome A2 Genotype Breast cancer Malignant tumor Epidemiology Mammary gland diseases Cancerology Risk factor Cytogenetics Genetics Single nucleotide polymorphism Public health Cancer Hormonal receptor |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c640t-9a9d0e508bc796da97f0d0ea9558f149d52878263aea069d6441eca4e6a3212b3 |
| Notes | istex:4A316F191C096D87AB5BEDF03186B9CAC98A9EA2 ark:/67375/HXZ-QBNCQ082-8 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://escholarship.org/content/qt17j916nm/qt17j916nm.pdf |
| PMID | 19567422 |
| PQID | 220992537 |
| PQPubID | 41605 |
| PageCount | 7 |
| ParticipantIDs | swepub_primary_oai_swepub_ki_se_557225 pubmedcentral_primary_oai_pubmedcentral_nih_gov_2724850 proquest_miscellaneous_67490121 proquest_miscellaneous_20211110 proquest_journals_220992537 pubmed_primary_19567422 pascalfrancis_primary_21718928 crossref_primary_10_1093_jnci_djp167 crossref_citationtrail_10_1093_jnci_djp167 oup_primary_10_1093_jnci_djp167 istex_primary_ark_67375_HXZ_QBNCQ082_8 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2009-07-15 |
| PublicationDateYYYYMMDD | 2009-07-15 |
| PublicationDate_xml | – month: 07 year: 2009 text: 2009-07-15 day: 15 |
| PublicationDecade | 2000 |
| PublicationPlace | Cary, NC |
| PublicationPlace_xml | – name: Cary, NC – name: United States – name: Oxford |
| PublicationTitle | JNCI : Journal of the National Cancer Institute |
| PublicationTitleAlternate | J Natl Cancer Inst |
| PublicationYear | 2009 |
| Publisher | Oxford University Press Oxford Publishing Limited (England) |
| Publisher_xml | – name: Oxford University Press – name: Oxford Publishing Limited (England) |
| References | Garcia-Closas ( key 20180328140411_bib4) 2008; 4 Antoniou ( key 20180328140411_bib6) 2003; 25 Easton ( key 20180328140411_bib1) 2007; 447 Hunter ( key 20180328140411_bib3) 2007; 39 Collins ( key 20180328140411_bib8) 2008; 100 Stacey ( key 20180328140411_bib7) 2008; 40 Stacey ( key 20180328140411_bib2) 2007; 39 StataCorp ( key 20180328140411_bib5) 2007 19567420 - J Natl Cancer Inst. 2009 Jul 15;101(14):973-5. doi: 10.1093/jnci/djp184. |
| References_xml | – volume: 39 start-page: 865 issue: 7 year: 2007 ident: key 20180328140411_bib2 article-title: Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer publication-title: Nat Genet. doi: 10.1038/ng2064 – volume: 25 start-page: 190 issue: 3 year: 2003 ident: key 20180328140411_bib6 article-title: Polygenic inheritance of breast cancer: implications for design of association studies publication-title: Genet Epidemiol doi: 10.1002/gepi.10261 – volume: 40 start-page: 703 issue: 6 year: 2008 ident: key 20180328140411_bib7 article-title: Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer publication-title: Nat Genet. doi: 10.1038/ng.131 – volume: 39 start-page: 870 issue: 7 year: 2007 ident: key 20180328140411_bib3 article-title: A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer publication-title: Nat Genet. doi: 10.1038/ng2075 – volume: 447 start-page: 1087 issue: 7148 year: 2007 ident: key 20180328140411_bib1 article-title: Genome-wide association study identifies novel breast cancer susceptibility loci publication-title: Nature doi: 10.1038/nature05887 – volume-title: Stata Statistical Software: Release 10.0 year: 2007 ident: key 20180328140411_bib5 – volume: 4 issue: 4 year: 2008 ident: key 20180328140411_bib4 article-title: Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics publication-title: PLoS Genet. doi: 10.1371/journal.pgen.1000054 – volume: 100 start-page: 218 issue: 3 year: 2008 ident: key 20180328140411_bib8 article-title: Comparison of estrogen receptor results from pathology reports with results from central laboratory testing publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djm270 – reference: 19567420 - J Natl Cancer Inst. 2009 Jul 15;101(14):973-5. doi: 10.1093/jnci/djp184. |
| SSID | ssj0000924 |
| Score | 2.298062 |
| Snippet | Background A recent genome-wide association study identified single-nucleotide polymorphism (SNP) 2q35-rs13387042 as a marker of susceptibility to estrogen... Background A recent genome-wide association study identified single-nucleotide polymorphism (SNP) 2q35-rs13387042 as a marker of susceptibility to estrogen... A recent genome-wide association study identified single-nucleotide polymorphism (SNP) 2q35-rs13387042 as a marker of susceptibility to estrogen receptor... Background: A recent genome-wide association study identified single-nucleotide polymorphism (SNP) 2q35-rs13387042 as a marker of susceptibility to estrogen... |
| SourceID | swepub pubmedcentral proquest pubmed pascalfrancis crossref oup istex |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1012 |
| SubjectTerms | Adult Aged Asian People - genetics Biological and medical sciences Biomarkers, Tumor - analysis Breast cancer Breast Neoplasms - chemistry Breast Neoplasms - genetics Breast Neoplasms - pathology Carcinoma, Ductal, Breast - chemistry Carcinoma, Ductal, Breast - genetics Carcinoma, Intraductal, Noninfiltrating - chemistry Carcinoma, Intraductal, Noninfiltrating - genetics Case-Control Studies Confidence Intervals Confounding Factors, Epidemiologic Estrogens Female Gene Frequency Genetic Predisposition to Disease Genotype Genotype & phenotype Gynecology. Andrology. Obstetrics Humans Linkage Disequilibrium Mammary gland diseases Medical sciences Middle Aged Neoplasms, Hormone-Dependent - chemistry Neoplasms, Hormone-Dependent - genetics Odds Ratio Oncology Polymorphism Polymorphism, Single Nucleotide Receptors, Estrogen - analysis Receptors, Progesterone - genetics Risk factors Tumors White People - genetics |
| Title | Risk of Estrogen Receptor–Positive and –Negative Breast Cancer and Single–Nucleotide Polymorphism 2q35-rs13387042 |
| URI | https://api.istex.fr/ark:/67375/HXZ-QBNCQ082-8/fulltext.pdf https://www.ncbi.nlm.nih.gov/pubmed/19567422 https://www.proquest.com/docview/220992537 https://www.proquest.com/docview/20211110 https://www.proquest.com/docview/67490121 https://pubmed.ncbi.nlm.nih.gov/PMC2724850 http://kipublications.ki.se/Default.aspx?queryparsed=id:119100575 |
| Volume | 101 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfGJiEkhPimDLY8THsAZcuc2IkfWTe0DVaxsUkTL5GTONC1NKVN-Xrif-DP442_hLvYcZtR0KAPUeqckzb3s-_Dd2dC1niUe75KfVegcyMIVeBGqeCur6JUhoHMkior7bDD906DgzN2trDwYyZqaVImG-nXuXkl_8NVaAO-YpbsP3DW3hQa4Bz4C0fgMBwvxeNjExe-Oy5HBVChEqiG6IU3IQz-qyom66NeI7CtHfVW1_vexpD08mkbWa-DKV-DKOurKSWWOy7KbqYwUu7L-wLYgttq0A8-c0djND1DTxeusipup71fORpmdN0qkrJ2O5qn2TAFy_NuX7tXjwtMRX65YV0FMDXiev5Oqd3dBxKF-dSNDcYAKMs6uQ3EaHfq3-32eqBF6w2YJzYSqnZyYF6Vq9M8bdIBCNNIb-izofRcHXDPBYuVNSZz4xoxqA1m5masZDYj57FU2VwZoutrnQ9S5H92PtzS-4U0a3VfkKE2slGv6fsxdo915ytkiYINg9tr7Oy_mKoJgpoS4fqfmeRR6LyJnTd154a6tIQj_3Odinl9KMcwjnO9Acs8C-n3QN9GOdxKhTq5SW4YPDjPNJBvkQU1uE2uHprojjvkE-LZKXKnxrNT4_nnt-81kh1AqQPfaww7GsOORlV1VWMYaSx6nVn0OhfQe5ecPt89ae-5ZmMQN-WBV7pCisxTYFokaSh4JkWYe9AgBWNRDiZ_xmgEmi_3pZIeFxnq_CqVgeLSB1Ut8e-RxUExUA-Ik_E0TxhXDPVckdEI7AdJZZbyhAZZnrbIk_r9x6mpmo-bt_TjOZxukTVLPNTFYuaTrVeMtDRy1MP4ypDFe2dv4qPtTvsINPM4apFV4PTfb7XSQIGlpVugdAoKt1iuYRGbmWscU8yXp8yH7qv2KogVXCuUA1VMgAR0f_h4f6bgYSCwIGSL3Ncgm_5OweAipS0SNuBnCbCkffPKoPuuKm1PQyyxCE9d10BtdDFNPThTMWMwpNjDy73xZXJtOqs8IovlaKIegzFRJivVoPwF1Nwi3A |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Risk+of+Estrogen+Receptor%E2%80%93Positive+and+%E2%80%93Negative+Breast+Cancer+and+Single%E2%80%93Nucleotide+Polymorphism+2q35-rs13387042&rft.jtitle=JNCI+%3A+Journal+of+the+National+Cancer+Institute&rft.au=Milne%2C+Roger+L.&rft.au=Ben%C3%ADtez%2C+Javier&rft.au=Nevanlinna%2C+Heli&rft.au=Heikkinen%2C+Tuomas&rft.date=2009-07-15&rft.issn=0027-8874&rft.eissn=1460-2105&rft.volume=101&rft.issue=14&rft.spage=1012&rft.epage=1018&rft_id=info:doi/10.1093%2Fjnci%2Fdjp167&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_jnci_djp167 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0027-8874&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0027-8874&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0027-8874&client=summon |